Amgen and Novartis Sue Each Other After Migraine Deal Collapses

(Bloomberg) -- Amgen Inc.’s multibillion-dollar collaboration with Novartis AG to jointly develop and market Amgen’s popular migraine-prevention treatment, Aimovig, triggered legal headaches for bo...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.